S&P Global Analysts Give Merck KGaA (MRK) a €110.00 Price Target
S&P Global set a €110.00 ($127.91) target price on Merck KGaA (FRA:MRK) in a research report report published on Thursday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other research firms also recently commented on MRK. Oddo Bhf set a €125.00 ($145.35) target price on Merck KGaA and gave the stock a buy rating in a report on Friday, September 29th. Morgan Stanley set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a neutral rating in a report on Monday, September 25th. Credit Suisse Group set a €106.00 ($123.26) target price on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) target price on Merck KGaA and gave the stock a neutral rating in a report on Thursday, August 17th. Finally, Kepler Capital Markets set a €119.00 ($138.37) target price on Merck KGaA and gave the stock a buy rating in a report on Monday, July 31st. Thirteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of €108.61 ($126.29).
Shares of Merck KGaA (FRA:MRK) opened at €90.33 ($105.03) on Thursday. Merck KGaA has a twelve month low of €89.21 ($103.73) and a twelve month high of €115.00 ($133.72).
TRADEMARK VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/s110-00-price-target.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.